Pharma BD Deal Intelligence
Positions Orion for Europe's Opdivo biosimilar wave; economics undisclosed and approval-gated
Full analysis, sources & comparables →Orion Pharma announces agreement with Shilpa Medicare (subsidiary Shilpa Biologicals) for an intravenous nivolumab biosimilar for the European market; Orion…
Legal/IP analysis of the Orion-Shilpa nivolumab biosimilar partnership for Europe, noting the expansion of an existing recombinant human albumin supply…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Orion Corporation and Shilpa Medicare's wholly owned subsidiary Shilpa Biologicals expanded their partnership with a co-development and supply agreement for an intravenous nivolumab biosimilar for Europe, announced July 6, 2026. Orion holds exclusive rights to register, market, distribute and sell the biosimilar across Europe and will act as Marketing Authorisation holder, while Shilpa Biologicals leads product development and serves as the exclusive long-term manufacturer and supplier from its EU-GMP biologics facility in Dharwad, India. Shilpa is entitled to development and regulatory milestone payments plus supply revenue over the life of the partnership; specific financial terms were not disclosed. The partnership targets a European market opportunity of approximately $4.1B based on 2025 reference-product sales as Opdivo approaches loss of exclusivity.
Non-small cell lung cancer is the most common form of lung cancer. Anti-PD-1 nivolumab is an established backbone across advanced/metastatic and perioperative NSCLC settings, making it one of the highest-volume indications for a nivolumab biosimilar in Europe.
The originator is Opdivo (nivolumab, Bristol Myers Squibb), an anti-PD-1 immune-checkpoint-inhibitor monoclonal antibody; the principal in-class competitor is Keytruda (pembrolizumab, Merck), also anti-PD-1. As Opdivo approaches loss of exclusivity in Europe, multiple developers are advancing nivolumab biosimilars; Shilpa's IV nivolumab biosimilar, commercialized by Orion, competes to capture EU checkpoint-inhibitor volume at a lower price point.
Nivolumab is also a standard immunotherapy across advanced melanoma and renal cell carcinoma (often combined with ipilimumab). These indications broaden the addressable European market for the biosimilar beyond lung cancer.
The originator is Opdivo (nivolumab, Bristol Myers Squibb), an anti-PD-1 immune-checkpoint-inhibitor monoclonal antibody; the principal in-class competitor is Keytruda (pembrolizumab, Merck), also anti-PD-1. As Opdivo approaches loss of exclusivity in Europe, multiple developers are advancing nivolumab biosimilars; Shilpa's IV nivolumab biosimilar, commercialized by Orion, competes to capture EU checkpoint-inhibitor volume at a lower price point.
Orion Pharma and Shilpa Biologicals (a Shilpa Medicare subsidiary) sign a co-development and supply agreement giving Orion exclusive rights to distribute, market and sell Shilpa's intravenous nivolumab biosimilar in Europe. Shilpa supplies the product and is entitled to development and regulatory milestone payments; financial terms were not disclosed.
The agreement extends an existing relationship (recombinant human albumin supply in Europe) into oncology, giving Orion a checkpoint-inhibitor biosimilar ahead of Opdivo's European loss of exclusivity. Outcome depends on biosimilar approval timing and EU price/volume dynamics.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Orion Corporation / Shilpa Biologicals Private Limited (this deal) | 2026 | — | 52 |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Servier / Agios Pharmaceuticals (oncology) | 2020 | $2.0B | 91 |
| Servier Pharmaceuticals LLC / Agios Pharmaceuticals Inc. | 2020 | $2.0B | 91 |
← Browse all deals · How we score deals
More: 2026 deals · Oncology deals